45 results about "Clear cell" patented technology

The present invention relates to a clear two-dimensional code which can be merged with an image without giving a user a feeling of disorder when the clear two-dimensional code is attached to the image and in which a readable situation and the like can be arbitrarily set; an article having the clear two-dimensional code attached thereto; a method for printing the two-dimensional code; and a method for displaying the two-dimensional code. Base cells and data cells are arranged in a matrix, and either the base cells or the data cells are clear. The clear two-dimensional code can be read only when a color shown on the clear cells consisting of either the base cells or the data cells and a color shown or non-clear cells consisting of either the base cells or the data cells have a contrast which can be read by a code recognition apparatus.

The invention discloses a blood cell separation method for portunus trituberculatus. The method comprises the following steps: diluting iodixanol with an isotonic solution obtained by regulating an osmotic pressure of a PBS buffer solution by utilizing a sodium chloride solution, and performing gradient preparation to obtain three iodixanol solutions of different concentrations; forming gradient solutions of different densities by adopting a cushion technology, and standing to form a continuous density gradient solution to serve as a cell separation solution; collecting blood cells of portunustrituberculatus, and taking mixed cell suspension obtained by diluting the isotonic solution; slowly dropping the mixed cell suspension into the cell separation solution, centrifuging, and dividing the blood cells of portunus trituberculatus into three layers, wherein the uppermost layer refers to clear cells, the intermediate layer refers to small granular cells, and the lowest layer refers to large granular cells. The method has the advantages that only one-step density gradient centrifugation is adopted, the operation is simple, and experiments discover that the separated blood cells haveexcellent viabilities and can be used for cell culture.

The invention discloses a mouse fibroblast and its application. in the field of cell biology. The cell is named mouse fibroblast MFC / HL‑041, and the deposit number is CCTCC NO: C201714. Mouse fibroblasts treated with drug mitogenin C or radiation irradiation are used for the separation and subculture of normal primary epithelial cells and primary tumor cells. The primary epithelial cells of human normal lung and lung cancer thus obtained are observed under a microscope, and they are fresh, densely arranged, with clear cell boundaries, strong three-dimensional sense, and polygonal epithelial cells. It can be used for physiological research of human or animal normal cells, virus infection model of normal cells in vitro, drug sensitivity detection of normal cells in vitro for different drugs, drug screening for individualized treatment of cancer patients and research and development of new anticancer drugs.

The invention discloses an application of acetaldehyde dehydrogenase 2 as a drug target for treating tumor cells with anthracycline type chemotherapy drugs. Drug screening shows that the anthracycline type chemotherapy drugs can specifically kill renal clear cell cancer cells with VHL deletion or mutation and has small toxicity to normal cells, thus providing an effective choice for chemotherapy of renal cancer and overcoming the disadvantage that the renal cancer is only treated through operations in clinical at present. Further study shows the sensitivity of the acetaldehyde dehydrogenase 2 mediated anthracycline type chemotherapy drugs to tumor cells, thus remaindering the application of the acetaldehyde dehydrogenase 2 as the drug target for treating tumor cells with the anthracycline type chemotherapy drugs. Deletion or mutation of the acetaldehyde dehydrogenase 2 exists in 40% of populations in Asia, so that the application of the acetaldehyde dehydrogenase 2 has a broader application prospect. For patients without the deletion or the mutation of the acetaldehyde dehydrogenase 2, killing effects on tumor cells can be significantly enhanced through combination of the anthracycline type chemotherapy drugs and an inhibitor of the acetaldehyde dehydrogenase 2.